Galapagos and Genentech extend drug discovery collaboration
(Thomson Reuters ONE) -
Mechelen, Belgium; 18 August 2011 - Galapagos NV (Euronext: GLPG) announced
today that its service division Argenta has extended its integrated contract
drug discovery agreement with Genentech, a member of the Roche Group (SIX: RO,
ROG; OTCQX: RHHBY). Total potential value of the contract extension is up to
£21.5 million (?23.4 million).
This is the third such extension since the agreement was announced in December
2005. The agreement covers a number of drug discovery programs that utilize
Argenta's expertise in computer-aided drug design (CADD), medicinal chemistry,
in vitro biology and screening to discover new chemical entities acting against
undisclosed drug targets defined by Genentech.
The extended agreement also allows Genentech to continue placing projects
directly into Galapagos' other service division, BioFocus, who will provide
Genentech with integrated medicinal chemistry, in vitro biology and ADME
services. BioFocus has been working with Genentech since an amendment to the
Argenta agreement was signed in September 2010.
"We are proud that Genentech again has selected Argenta for this major drug
discovery collaboration," said Dr Chris Newton, SVP Services of Galapagos. "The
possibility for Genentech to continue placing projects directly with BioFocus
also speaks to the complementary expertise and technological capabilities that
Argenta and BioFocus possess."
About Argenta
Argenta's contract research, which includes expertise in medicinal chemistry,
computer-aided drug discovery,in vitro biology, analytics, in vivo
pharmacokinetics, pharmacology and world-leading respiratory models, has a
strong reputation for scientific excellence. Argenta is a service division of
Galapagos NV (Euronext: GLPG) and employs over 140 people in the UK with its
main operations in Harlow. More info at: www.argentadiscovery.com
About BioFocus
BioFocus delivers drug discovery solutions through a comprehensive platform run
by dedicated teams with a track record in gene-to-clinical candidate discovery.
BioFocus' offering includes target discovery in human primary cells, focused as
well as diverse compound libraries, in vitro and cell-based screening,
structural biology, medicinal chemistry and ADME/PK services, supported by
unique chemogenomic and informatics tools. As a service division of Galapagos,
BioFocus has over 210 employees with research facilities in three countries.
For more information visit www.biofocus.com
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing one of the
largest pipelines in biotech, with six programs in development and over 50
discovery programs. Through risk/reward-sharing alliances with GlaxoSmithKline,
Lilly, Janssen Pharmaceutica, Roche and Servier, Galapagos is eligible to
receive up to ?2.5 billion in downstream milestones, plus royalties. The
Galapagos Group has about 800 employees and operates facilities in six
countries, with global headquarters in Mechelen, Belgium. More info at:
www.glpg.com
CONTACT
Galapagos NV
Dr Chris Newton, SVP Services
Tel: +44 1799 533 535
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir(at)glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1539119]
Unternehmensinformation / Kurzprofil:
Datum: 18.08.2011 - 07:36 Uhr
Sprache: Deutsch
News-ID 57349
Anzahl Zeichen: 5705
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 182 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos and Genentech extend drug discovery collaboration"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
